Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrEP-India: Daily Oral PrEP for Female Sex Workers
NCT02148094Phase 1Completed
- Sponsor
- University of Manitoba
- Start
- Jan 2016
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by University of Manitoba. Primary endpoint: Sustained uptake and adherence to oral PrEP among female sex workers at 24 months. Started Jan 2016; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02148094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02148094.